Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Apr 11, 2017
Jason Sheltzer, a cancer biologist at Cold Spring Harbor Laboratory in New York, was on the hunt for genes involved in tumour growth. He and his colleagues planned to disable the MELK gene using the popular gene-editing tool CRISPR–Cas9, then look for changes that reduced the rate at which cancer cells multiply. The...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper